C37
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with histologically proven thymic epithelial tumours (thymoma and thymic carcinoma), thymic hyperplasia and/or a diagnosis of myasthenia gravis. 2. Treatment at the Department of Thoracic Surgery at the University of Freiburg Medical Center between January 2006 and September 2022 3. Written informed consent from living individuals or meeting the criteria defined in the “Merkblatt zur Nutzung von Altproben” (Version November 2014) of the ethics committee. 4. Sufficient tissue availability at the Institute of Clinical Pathology.
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of CD26/DPP4 in thymic epithelial tumours and thymic tissue of patients with myasthenia gravis. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To correlate the expression of CD26/DPP4 with the histologic subtype, TNM and Masaoka-Koga Stadium, the overall and relapse-free survival in thymic epithelial tumours. - To correlate the expression of CD26/DPP4 in thymic tissue with the clinical course in patients with Myasthenia gravis | — |
Countries
Germany
Contacts
Universitätsklinikum Freiburg, Klinik für Thoraxchirurgie